{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055521","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.197672+00:00","generated_at":"2026-05-20T02:58:32.898462+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outlook Therapeutics launches LYTENAVA (bevacizumab gamma) in Germany and UK for wet AMD","bullets":["Commercial launch of LYTENAVA (bevacizumab gamma) in Germany and UK announced on June 2, 2025.","Indication: treatment of wet age-related macular degeneration (wet AMD).","First approved bevacizumab gamma product for wet AMD in these two markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055521","json":"https://secwatch.observer/filing/0001104659-25-055521.json","markdown":"https://secwatch.observer/filing/0001104659-25-055521.md","text":"https://secwatch.observer/filing/0001104659-25-055521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/0001104659-25-055521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925055521/tm2516951d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:58:32.898462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}